Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.
|
|
- Dortha Neal
- 5 years ago
- Views:
Transcription
1 Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER Publications Office AATS Annual Meeting 2015 Seattle, WA April 27, 2015
2 Disclosure Statement of Financial Interest Wilson Y. Szeto, MD Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Investigator, Steering committee member of the PARTNER trial Company Edwards Lifesciences
3 Background Surgical aortic valve replacement (SAVR) is being challenged by transcatheter aortic valve replacement (TAVR) for patients considered at high surgical risk. There is increasing pressure on surgeons and institutions to improve quality metrics and outcomes while reducing cost of medical care. Surgeons considering SAVR in high risk patients risk failing quality metrics.
4 Objectives / Questions The Placement of Aortic Transcatheter Valves (PARTNER) trial provides insight into outcomes after surgical AVR in high-risk patients at extreme of traditional indications for SAVR. 1) Are surgical outcomes after high risk SAVR accurately predicted by current national benchmarks? 2) Is intermediate term survival after high risk AVR commensurate with that of the matched general population seen in previous studies? 3) Is there a subset of elderly patients whose risk of mortality after SAVR is exceptionally high (with survival worse than treatment without AVR, i.e. futility)?
5 Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened Cohort A (High Surgical Risk) n=699 Cohort B (Inoperable) n=358 Allocated to SAVR n=351 Allocated to Medical Therapy n=179 Did not undergo SAVR (n=38) - Died before procedure: 5 - Deteriorated before procedure: 5 - Refused: 17 - Withdrew: 11 Allocated to TAVR (n=348) Allocated to TAVR (n=179) Crossover from TAVR to Medical Therapy: 2 Received Medical Therapy n=181 ReceivedSAVR n=351
6 Patient Population 699 patients with severe symptomatic AS were enrolled into PARTNER 1A from Of the 351 patients randomized to SAVR, 313 underwent AVR (as treated cohort). 28 patients withdrew / refused therapy 10 patients deteriorated to an inoperable status 181 patients in PARTNER 1B (inoperable cohort) randomized to medical therapy were used as reference for survival without valve replacement.
7 Methodology Procedural outcome and primary safety endpoints were compared to national quality benchmarks for SAVR defined according to the STS Database Version Intermediate term survival comparison with matched general population was performed using 2008 US life tables. Incremental risk factors for mortality were identified from 102 possible risk factors.
8 Patient Characteristics (1) Demographics No. (%) or Mean ± SD Female 134 (43) Age (y) 84 ± 6.3 Body Mass Index (kg/m 2 ) 27 ± 5.7 Symptoms NYHA Class 3 or (95) Predicted operative mortality By benchmark available at time of enrollment (%) Cardiac Comorbidities 12 ± 3.4 Coronary Artery Disease 241 (77) Previous MI 90 (29) Atrial Fibrillation 69 (22)
9 Patient Characteristics (2) No. (%) or Mean ± SD Non-Cardiac Comorbidities Peripheral Arterial Disease 210 (67) CVD 108 (35) Diabetes 128 (41) Chronic Pulmonary Disease 147 (47) Renal Disease 69 (22) Hepatic Disease 9 (2.9) Previous Procedures PCI 101 (32) CABG 140 (45) Pacemaker 70 (22) Echocardiographic Characteristics AV peak velocity (cm/sec) 422 ± 70 AV area (cm 2 ) 0.64 ± 0.19 AV mean gradient (mmhg) 43 ± 14 Ejection fraction (%) 53 ± 12
10 Operative Details / Variables (1) No. (%) or Mean ± SD Incision Full sternotomy 243 (78) Partial sternotomy 51 (16) Thoracotomy 18 (5.8) Aortic valve prosthesis Valve size (mm) (12) (40) (35) (12) 27 3 (0.97)
11 Operative Details / Variables (2) No. (%) or Mean ± SD Prosthesis type Edwards Lifesciences 273 (87) St. Jude 3 (0.95) Carbomedics mechanical 4 (1.3) Medtronic 12 (3.8) Sorin 7 (2.2) Unspecified porcine 1 (0.32) Unspecified 13 (4.2) Concomitant procedure Unanticipated CABG 21 (6.7) Support Aortic clamp time (min) 74 ± 29 Cardiopulmonary bypass time (min) 105 ± 41
12 Outcome Referenced to Contemporary STS Benchmarks Outcome Observed No. (%) Expected No. (%) Observed/Expected (68% CL) p Operative mortality 33 (10) 29 (9.3) 1.14 ( ) 0.40 Stroke 8 (2.6) 11 (3.5) 0.73 ( ) 0.40 Renal Failure 18 (5.8) 38 (12) 0.48 ( ) Deep sternal wound infection 2 (0.64) 1.03 (0.33) 1.94 ( ) 0.30 Postoperative length of stay > 14 days 83 (26) 56 (18) 1.48 ( ) <0.0001
13 Worse Survival Compared to Age Matched Population % SAVR Years
14 Incremental Risk Factors for Mortality after SAVR Risk Factor Coefficient ± SE p Hazard Ratio (68% CL) Reliability (%) a Early decreasing hazard Previous CABG (less risk) ± ( ) 88 Lower albumin b 7.0 ± n/a 51 Longer aortic clamp time c 0.95 ± n/a 60 Intermediate-term hazard Smaller BMI d 0.99 ± n/a 64 History of cancer 0.86 ± ( ) 59 Severe prosthesispatient mismatch a. Percent of times variables appeared in 1000 bootstrap models b. (1/albumin), inverse transformation c. Log (aortic clamp time/75), logarithmic transformation d. (25/BMI) 2, inverse squared transformation 0.77 ± ( ) 86
15 Survival Prior CABG % Yes No Years
16 Survival (%) 1 Year Survival - Albumin Albumin (g/dl)
17 Survival (%) 1 Year Survival - Aortic Clamp Time Aortic Clamp Time (min)
18 Survival (%) 1 Year Survival - BMI Body Mass Index
19 Survival Cancer % No Yes Years
20 % Survival Moderate Mismatch None/Mild Severe Years
21 Survival: SAVR vs Medical Therapy 100 % SAVR Medical Therapy Years
22 Survival Medical Therapy % SAVR Age = 70 BMI = 36 Albumin = 2.9 Cancer Years
23 Survival Medical Therapy % SAVR Age = 90 BMI = 27 Albumin = 3.04 Cancer Years
24 % SAVR Age = 86 BMI = 21 Cancer Previous CABG Survival Medical Therapy Years
25 Conclusions (1) PARTNER 1A SAVR outcome was similar to contemporary benchmarks, suggesting these benchmarks may underestimate risk across high risk profiles. PARTNER 1A SAVR patients had worse survival compared to matched US population, suggesting a less selected population with higher morbidities and risk profile.
26 Conclusions (2) PARTNER 1A SAVR patients have improved survival compared to PARTNER 1B patients randomized to medical therapy, although a few selected risk profiles demonstrated the futility of SAVR with worse outcome. PARTNER selection criteria for SAVR may be more appropriate and realistic, thus reflecting the contemporary surgical management of severe aortic stenosis in high risk patients.
27 Thank you to the dedicated study teams at all the PARTNER Sites! Special thanks to the participants in this writing group Lars G. Svensson Jeevanantham Rajeswaran John Ehrlinger Rakesh M. Suri Craig R. Smith Michael Mack D. Craig Miller Patrick M. McCarthy Joseph E. Bavaria Lawrence H. Cohn Paul J. Corso Robert A. Guyton Vinod H. Thourani Bruce W. Lytle Mathew R. Williams John G. Webb Samir Kapadia E. Murat Tuzcu David J. Cohen Hartzell V. Schaff Martin B. Leon Eugene H. Blackstone
Aortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationOutcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era
Outcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era Sebastian A. Iturra, Rakesh M. Suri, Kevin L. Greason, John
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationVinod H. Thourani, MD, FACC, FACS
Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationEarly and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients
Early and One-year Outcomes of Aortic Root Surgery in Marfan Syndrome Patients A Prospective, Multi-Center, Comparative Study Joseph S. Coselli, Irina V. Volguina, Scott A. LeMaire, Thoralf M. Sundt, Elizabeth
More informationFor the SURTAVI Investigators
Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationTAVR for Complex Aortic Valvular Conditions
TAVR for Complex Aortic Valvular Conditions Wilson Y. Szeto, MD Professor of Surgery Chief, Cardiovascular Surgery at Penn Presbyterian Surgical Director, Transcatheter Cardio-Aortic Therapies Associate
More informationUsing STS/ACC TVT Registry Data for Quality Improvement (QI) Learning Objectives. Overview 3/12/2014
Using STS/ACC TVT Registry Data for Quality Improvement (QI) March 27, 2014 Kim Marshall BSN, RN Quality Improvement Specialist We Improve Lives Learning Objectives Sources for data analysis for Transcatheter
More informationEstablishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationClinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients Susheel Kodali, MD on behalf of The PARTNER Trial Investigators
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationWelcome to the 10 th Annual Meeting of ISMPP! Leading Through Collaboration
Welcome to the 10 th Annual Meeting of ISMPP! Leading Through Collaboration 1 The PARTNER Publications Office (PPO) Why PPO? Obstacles to publication Access to data Availability of resources Time management
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationCARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE
ESC Congress 2011 27 Aug - 31 Aug 2011, Paris - France CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE N.Russo, L.Compostella, T.Setzu, M.Napodano, L.Testolin,
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationProspective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease
Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Background Frailty is a common occurrence in elderly patients Approximately half of the
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationOutcome of elderly patients with severe but asymptomatic aortic stenosis
Outcome of elderly patients with severe but asymptomatic aortic stenosis Robert Zilberszac, Harald Gabriel, Gerald Maurer, Raphael Rosenhek Department of Cardiology Medical University of Vienna ESC Congress
More informationPolicy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationTranscatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis: Final Results from the PARTNER 2A Trial
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis: Final Results from the PARTNER 2A Trial Craig R. Smith, MD on behalf of the PARTNER Trial Investigators
More informationOutcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,
More informationValve Disease. Valve Surgery. In 2015, Cleveland Clinic surgeons performed 2943 valve surgeries.
Valve Surgery 11 15 Volume 3 1 11 1 13 1 N = 1 773 5 79 15 93 In 15, surgeons performed 93 valve surgeries. surgeons have implanted more than 1,5 bioprosthetic aortic valves since the 199s, with excellent
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationStrokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationPercutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington
Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationIncidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients. An STS/ACC TVT Registry Report
Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients An STS/ACC TVT Registry Report Howard C. Herrmann, MD University of Pennsylvania Philadelphia Howard C. Herrmann
More informationRISK PREDICTION IN TAVR. Beyond STS PROM and the Eyeball Assessment
RISK PREDICTION IN TAVR Beyond STS PROM and the Eyeball Assessment SAVR VS TAVR BIOPROSHETIC OPEN SURGICAL VALVE (SAVR) BIOPROSTHETIC TRANSCATHETER VALVE (TAVR) This Photo by Unknown Author is licensed
More informationOutcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and
Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 6/2018 Origination: 2/2012 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationIn Process, Unpublished STS/ACC TVT Registry Manuscripts
In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript
More informationMitral Valve Surgery: Lessons from New York State
Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman & Program Director Department of Cardiovascular
More informationValve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries.
Valve Surgery Total Volume 1 1 Volume 35 3 5 15 1 5 1 13 1 N = 773 5 79 15 93 1 339 In 1, surgeons performed 339 valve surgeries. surgeons have implanted more than 1, bioprosthetic aortic valves since
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationMatthew R. Reynolds, M.D., M.Sc. On Behalf of the PARTNER Investigators
Lifetime Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Standard Care Among Inoperable Patients with Severe Aortic Stenosis: Results from the PARTNER Trial (Cohort B) Matthew
More informationTranscatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationEffect of Concomitant Coronary Artery Disease on Procedural and Late Outcomes of Transcatheter Aortic Valve Implantation
ADULT CARDIAC Effect of Concomitant Coronary Artery Disease on Procedural and Late Outcomes of Transcatheter Aortic Valve Implantation Todd M. Dewey, MD, David L. Brown, MD, Morley A. Herbert, PhD, Dan
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationDisclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb
Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft
More informationThe PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial II
Department of Medicine Director, Transcatheter Aortic Valve Program June 2013 [First Name] [Last Name], [Suffix] [Hospital or Practice Name] [Address] [City], [State] [Zip] Dear Dr. [Last name], We are
More informationOne Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry David R. Holmes, Jr., J. Matthew Brennan, John S. Rumsfeld, David Dai, Fred Edwards, John Carroll, David Shahian, Fred Grover,
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationTranscatheter Heart Valve Procedures
Medical Coverage Policy Transcatheter Heart Valve Procedures Table of Contents Coverage Policy... 1 Overview... 2 General Background... 2 Coding/Billing Information... 27 References... 29 Effective Date...11/15/2017
More informationAre Heart Valve Referral Centers Feasible in Latin America?
Are Heart Valve Referral Centers Feasible in Latin America? Vadim Kotowicz, MD Chief of Cardiovascular Surgery Department Italian Hospital of Buenos Aires Disclosure Medtronic inc. Consultanting Johnson
More informationLow Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor
Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationOptions for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: Original Effective Date: MM.06.019 10/01/2012 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/27/2018
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationACCESS-EUROPE Phase I
ACCESS-EUROPE Phase I A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year Wolfgang Schillinger, MD on behalf of the
More informationPercutaneous Aortic Valvuloplasty: Long-Term Survival
Percutaneous Aortic Valvuloplasty: Long-Term Survival Angioplasty Summit Seoul April 27, 2007 James R. Margolis MD Carmen Paez MD, Kevin Coy MD, Edward Freeman PhD Miami International Cardiology Consultants
More informationArticles. Funding Edwards Lifesciences.
5-year outcomes of transcatheter aortic valve replacement compared with standard for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial Samir R Kapadia, Martin B Leon,
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationAPOLLO TMVR Trial Update: Case Presentation
APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationSaudi Heart Association. Raising Standards through Education and Training
Saudi Heart Association Raising Standards through Education and Training 25th Annual Meeting EACTS Lisbon, Oc ctober 2011 WWW EA WWW. ACTS ORG ACTS.ORG Clinical decision making in case of Aortic valve
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: Original Effective Date: MM.06.019 10/01/2012 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/26/2017
More informationIn Process, Unpublished STS/ACC TVT Registry Manuscripts
In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript
More information